Cargando…

In vitro activities of contezolid (MRX-I) against drug-sensitive and drug-resistant Mycobacterium tuberculosis

A novel oxazolidinone for the treatment of Mycobacterium tuberculosis has been developed, but the activity of contezolid (MRX-I) still needs to be clarified. In this study, we isolated Mycobacterium tuberculosis from 48 clinical patients with pulmonary tuberculosis. Roche drug susceptibility tests i...

Descripción completa

Detalles Bibliográficos
Autores principales:	An, Huiru, Sun, Wenna, Liu, Xiao, Wang, Tianhao, Qiao, Juan, Liang, Jianqin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2023
Materias:	Observation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10580816/ https://www.ncbi.nlm.nih.gov/pubmed/37732805 http://dx.doi.org/10.1128/spectrum.04627-22

Ejemplares similares

Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus
por: Gao, Shan., et al.
Publicado: (2023)

A Novel Oxazolidinone, Contezolid (MRX-I), Expresses Anti-Mycobacterium abscessus Activity In Vitro
por: Guo, Qi, et al.
Publicado: (2021)

2148. In vitro Potency of a Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Against Mycobacterium tuberculosis, Mycobacterium avium, and Mycobacterium abscessus
por: Shoen, Carolyn M, et al.
Publicado: (2023)

697. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
por: Yang, Yang, et al.
Publicado: (2019)

686. Evaluation of Contezolid Activity to Anaerobic and Gram-positive-cocci Isolates from a Phase 3 Acute Bacterial Skin and Skin Structure Infection Clinical Trial (MRX-I-06)
por: Yang, Yang, et al.
Publicado: (2019)

Contezolid: First Approval
por: Hoy, Sheridan M.
Publicado: (2021)

In Vitro Activity of Cefiderocol against Extensively Drug-Resistant Pseudomonas aeruginosa: CANWARD, 2007 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

Enhanced Specialized Transduction Using Recombineering in Mycobacterium tuberculosis
por: Tufariello, JoAnn M., et al.
Publicado: (2014)

1118. Population Pharmacokinetics of Contezolid Acefosamil and Contezolid – Rationale for a Safe and Effective Loading Dose Regimen
por: Bulitta, Jürgen B, et al.
Publicado: (2021)

A Mycobacterium tuberculosis Cytochrome bd Oxidase Mutant Is Hypersensitive to Bedaquiline
por: Berney, Michael, et al.
Publicado: (2014)

Sterilization by Adaptive Immunity of a Conditionally Persistent Mutant of Mycobacterium tuberculosis
por: Vilchèze, Catherine, et al.
Publicado: (2021)

Correlation between Disease Severity and the Intestinal Microbiome in Mycobacterium tuberculosis-Infected Rhesus Macaques
por: Namasivayam, Sivaranjani, et al.
Publicado: (2019)

A revised SNP-based barcoding scheme for typing Mycobacterium tuberculosis complex isolates
por: Shitikov, Egor, et al.
Publicado: (2023)

Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients
por: Wang, Jun, et al.
Publicado: (2023)

Contezolid, a novel oxazolidinone antibiotic, may improve drug-related thrombocytopenia in clinical antibacterial treatment
por: Li, Bi, et al.
Publicado: (2023)

In Vitro Activity of MRX-8 and Comparators Against Clinical Isolated Gram-Negative Bacilli in China
por: Wu, Shi, et al.
Publicado: (2022)

SigH stress response mediates killing of Mycobacterium tuberculosis by activating nitronaphthofuran prodrugs via induction of Mrx2 expression
por: Cioetto-Mazzabò, Laura, et al.
Publicado: (2022)

1700. Efficacy and Safety in Subjects with Renal Impairment in Contezolid and Contezolid Acefosamil Phase 2 and Phase 3 Skin Infection Clinical Trials
por: Fang, Edward, et al.
Publicado: (2022)

Pharmacological Inhibition of Host Heme Oxygenase-1 Suppresses Mycobacterium tuberculosis Infection In Vivo by a Mechanism Dependent on T Lymphocytes
por: Costa, Diego L., et al.
Publicado: (2016)

Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
por: Macho, Markéta, et al.
Publicado: (2022)

A Novel Leucyl-tRNA Synthetase Inhibitor, MRX-6038, Expresses Anti-Mycobacterium abscessus Activity In Vitro and In Vivo
por: Wu, Wenye, et al.
Publicado: (2022)

Omadacycline Is Highly Active In Vitro against Mycoplasma genitalium
por: Waites, Ken B., et al.
Publicado: (2022)

662. In vitro antibacterial activity of contezolid compared to linezolid and vancomycin in clinical isolates from China
por: Wang, Shanmei, et al.
Publicado: (2022)

Mechanism of MRX inhibition by Rif2 at telomeres
por: Roisné-Hamelin, Florian, et al.
Publicado: (2021)

Indoleamides are active against drug-resistant Mycobacterium tuberculosis
por: Lun, Shichun, et al.
Publicado: (2013)

Identification of Mycobacterium pseudoshottsii in the Eastern Mediterranean
por: Davidovich, Nadav, et al.
Publicado: (2023)

Drug Resistance Mechanisms in Mycobacterium tuberculosis
por: Palomino, Juan Carlos, et al.
Publicado: (2014)

A Novel, Rapid, and Low-Volume Assay for Therapeutic Drug Monitoring of Posaconazole and Other Long-Chain Azole-Class Antifungal Drugs
por: Wiedman, Gregory R., et al.
Publicado: (2018)

Preliminary evaluation of anti-tuberculosis potential of siderophores against drug-resistant Mycobacterium tuberculosis by mycobacteria growth indicator tube-drug sensitivity test
por: Gokarn, Karuna, et al.
Publicado: (2017)

Propargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosis
por: Hajian, Behnoush, et al.
Publicado: (2016)

Developing Synergistic Drug Combinations To Restore Antibiotic Sensitivity in Drug-Resistant Mycobacterium tuberculosis
por: Omollo, Charles, et al.
Publicado: (2021)

In vitro Activity of Contezolid Against Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus, and Strains With Linezolid Resistance Genes From China
por: Wang, Siheng, et al.
Publicado: (2021)

In Vitro Evaluation of the Activity of Aztreonam-Avibactam against 341 Recent Clinical Isolates of Anaerobes
por: Snydman, David R., et al.
Publicado: (2021)

Novel Treatments against Mycobacterium tuberculosis Based on Drug Repurposing
por: Mourenza, Álvaro, et al.
Publicado: (2020)

Clinical Characteristics and Treatment Outcomes of Mycobacterium fortuitum Pulmonary Disease
por: Kim, Sae Rom, et al.
Publicado: (2023)

Mycobacterium tuberculosis in central Ethiopia: drug sensitivity patterns and association with genotype
por: Bedewi, Z., et al.
Publicado: (2017)

In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden
por: Camporeale, Angela, et al.
Publicado: (2021)

In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection
por: Albano, Mariana, et al.
Publicado: (2021)

Draft Genome Sequences of Local Clinical Isolates of Drug-Resistant and Drug-Sensitive Mycobacterium tuberculosis
por: Zainal Abidin, Norzuliana, et al.
Publicado: (2021)

In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients
por: Ying, Ruoyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1o0dq4g8f5q0qnvfpdrekvh6fb